RecruitingNot ApplicableNCT07579702

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes and Suboptimal Glycemia

Sponsor

Insulet Corporation

Enrollment

200 participants

Start Date

May 13, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus

Summary

This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

Eligibility

Min Age: 14 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Omnipod 5 System and a medical device called Omnipod 6 System for people with type 1 diabetes mellitus and type 2 diabetes mellitus. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 14 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEOmnipod 5 System

The Omnipod 5 System with the study CGM

DEVICEOmnipod 6 System

The Omnipod 6 System with the study CGM

Locations(12)

University of Southern California

Los Angeles, California, United States

Sansum Diabetes Research Institute

Santa Barbara, California, United States

University of Colorado

Aurora, Colorado, United States

Yale

New Haven, Connecticut, United States

University of South Florida

Tampa, Florida, United States

Emory University

Atlanta, Georgia, United States

Northwestern University

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

Joslin Diabetes Center

Boston, Massachusetts, United States

Henry Ford Health Systems

Detroit, Michigan, United States

Health Partners

Minneapolis, Minnesota, United States

Baylor College of Medicine

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07579702

Related Trials

Pediatric Insulin Plan Calculator for T1DM Management

NCT074271342 locations

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068159 locations

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

NCT0722811738 locations

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

NCT071422523 locations

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

NCT0611158679 locations